{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:42Z","timestamp":1790960802047,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Six non-ergot dopamine -receptor agonists (NEDAs), including pramipexole extended-release (ER), pramipexole immediate-release (IR), rotigotine patch, piribedil, ropinirole prolonged-release (PR), and ropinirole IR, are frequently used to treat early Parkinson\u2019s disease (PD). However, there is a paucity of comparative information about them. For making rational drug selections, six NEDAs were evaluated using a rapid health technology assessment method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>According to the rapid guidelines for drug evaluation and selection in Chinese medical institutions (the Second Edition), the pharmacological properties, efficacy, safety, economy, and other attributes of six NEDAs were scored on a percentage system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The composite scores of the six NEDAs are presented as follows: 74.99 points for pramipexole ER, 74.90 points for piribedil, 72.40 points for pramipexole IR, 70.78 points for rotigotine patch, 69.06 points for ropinirole PR and 68.41 points for ropinirole IR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our comprehensive multi-criteria assessment, pramipexole ER, pramipexole IR, rotigotine patch, and piribedil are strongly recommended for inclusion in the formularies of medical institutions as therapeutic options for patients with early PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1648833","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:20:58Z","timestamp":1765948858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Jieqiong","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Li","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]},{"name":"Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]},{"name":"Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]},{"name":"Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Lai","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]},{"name":"Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jval.2023.05.015","article-title":"The evolving nature of health technology assessment: a critical appraisal of NICE's new methods manual","volume":"26","author":"Angelis","year":"2023","journal-title":"Value Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson's disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","article-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis","volume":"76","author":"Binde","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2174\/157015911795596577","article-title":"Medical management of Parkinson's disease: focus on neuroprotection","volume":"9","author":"Boll","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","article-title":"Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome","volume":"46","author":"Boroojerdi","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14740338.2016.1130128","article-title":"A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease","volume":"15","author":"Ceravolo","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3760\/cma.j.issn.0254-9026.2016.04.001","article-title":"Prevention and treatment strategies for motor complications of Parkinson's disease","volume":"35","author":"Chen","year":"2016","journal-title":"Chin. J. Geriatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3760\/cma.j.cn113694-20200331-00233","article-title":"Chinese guidelines for the treatment of Parkinson's disease (the fourth edition) (Chinese)","volume":"53","author":"Chen","year":"2020","journal-title":"Chin. J. Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5582\/bst.2018.01038","article-title":"Development of health technology assessment in China: new challenges","volume":"12","author":"Chen","year":"2018","journal-title":"Biosci. Trends"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1183823","DOI":"10.3389\/fneur.2023.1183823","article-title":"Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.11.007","article-title":"Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease","volume":"61","author":"Contin","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The parkinson Pandemic-A call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","article-title":"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome","volume":"75","author":"Elshoff","year":"2015","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","article-title":"Canadian guideline for Parkinson disease","volume":"191","author":"Grimes","year":"2019","journal-title":"CMAJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jclinepi.2020.09.041","article-title":"Defining rapid reviews: a systematic scoping review and thematic analysis of definitions and defining characteristics of rapid reviews","volume":"129","author":"Hamel","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1586\/ern.11.122","article-title":"Pramipexole extended release in Parkinson's disease","volume":"11","author":"Hametner","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2165\/00019053-199814050-00006","article-title":"Cost effectiveness of pramipexole in Parkinson's disease in the US","volume":"14","author":"Hoerger","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.clinthera.2009.10.018","article-title":"Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies","volume":"31","author":"Jenner","year":"2009","journal-title":"Clin. Ther."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3870\/j.issn.1004-0781.2025.02.013","article-title":"Comprehensive evaluation of original research sodium-glucose transporters 2 inhibitors (SGLT-2 inhibitors) based on the quick guide for drug evaluation and selection in Chinese medical institutions (second edition)","author":"Ji","year":"2025","journal-title":"Her. Med."},{"key":"B24","volume-title":"Cost-effectiveness evaluation of rotigotine versus pramipexole in the treatment of Parkinson's disease","author":"Jiang","year":"2020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2174\/1570159X20666220915091022","article-title":"Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson's disease","volume":"21","author":"Jing","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/cns.12727","article-title":"Adverse effects produced by different drugs used in the treatment of Parkinson's disease: a mixed treatment comparison","volume":"23","author":"Li","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40035-019-0162-z","article-title":"Parkinson's disease in China: a forty-year growing track of bedside work","volume":"8","author":"Li","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"B28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2\/D3 receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"B29","unstructured":"Pramipexole dihydrochloride\u2122 tablets [EB\/OL]. 2017-05-26\n          \n          \n          2017"},{"key":"B30","unstructured":"Piribedil Sustained-release Tablets\u2122 label [EB\/OL]. 2013-05-10\n          \n          \n          2013"},{"key":"B31","unstructured":"Pramipexole Dihydrochloride Sustained-release Tablets\u2122 label [EB\/OL]"},{"key":"B32","unstructured":"Ropinirole Hydrochloride Sustained-release\u2122 label"},{"key":"B33","unstructured":"Ropinirole Hydrochloride Tablets\u2122 label\n          \n          \n          2016"},{"key":"B34","unstructured":"Rotigotine Paches\u2122 label [EB\/OL]\n          \n          \n          2018"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2165\/00019053-200523120-00009","article-title":"Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness","volume":"23","author":"Noyes","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-016-0360-5","article-title":"Piribedil for the treatment of motor and non-motor symptoms of parkinson disease","volume":"30","author":"Perez-Lloret","year":"2016","journal-title":"CNS Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","article-title":"Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial","volume":"77","author":"Poewe","year":"2011","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","article-title":"Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease","volume":"25","author":"Sanford","year":"2011","journal-title":"CNS Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3969\/j.issn.1006-2963.2021.04.001","article-title":"Evidence based medicine guidelines for the treatment of early motor symptoms of Parkinson's disease in China (Chinese)","volume":"28","author":"Su","year":"2021","journal-title":"Chin. J. Neuroimmunology Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"660340","DOI":"10.3389\/fnins.2021.660340","article-title":"Comparing the clinical and neuropsychological characteristics of Parkinson's Disease with and without freezing of gait","volume":"15","author":"Taximaimaiti","year":"2021","journal-title":"Front. Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2047-9158-3-11","article-title":"The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study","volume":"3","author":"Wang","year":"2014","journal-title":"Transl. Neurodegener."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7909","DOI":"10.2147\/DDDT.S535347","article-title":"Health technology assessment: evaluation of monoclonal antibodies for the treatment of Neuromyelitis Optica spectrum disorders","volume":"19","author":"Wang","year":"2025","journal-title":"Drug Des. Devel Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e48717","DOI":"10.7759\/cureus.48717","article-title":"The efficacy, safety, and economic outcomes of using ferric derisomaltose for the management of iron deficiency in China: a rapid health technology assessment","volume":"15","author":"Yun","year":"2023","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3870\/j.issn.1004-0781.2023.04.001","article-title":"Rapid guidelines for drug evaluation and selection in Chinese medical institutions","author":"Zhao","year":"2023","journal-title":"Her. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1648833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:03:28Z","timestamp":1768899808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1648833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":45,"alternative-id":["10.3389\/fphar.2025.1648833"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1648833","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1648833"}}